Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 277Precursor Cell Lymphoblastic Leukemia-Lymphoma 55Recurrence 43Neoplasms, Plasma Cell 32Leukemia 29Lymphoma 25Neoplasms 23Vomiting 21Burkitt Lymphoma 20Lymphoma, Non-Hodgkin 19Nausea 17Immunoglobulin Light-chain Amyloidosis 17Lymphoma, Mantle-Cell 16Carcinoma, Non-Small-Cell Lung 15Prostatic Neoplasms 14Waldenstrom Macroglobulinemia 13Lymphoma, Follicular 13Breast Neoplasms 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11Lymphoma, Large B-Cell, Diffuse 11Leukemia, Myeloid, Acute 10Lymphoma, B-Cell, Marginal Zone 9Amyloidosis 9Leukemia, Lymphocytic, Chronic, B-Cell 8Hodgkin Disease 8Neoplasm Metastasis 7Hematologic Neoplasms 7Smoldering Multiple Myeloma 6Ovarian Neoplasms 6Lung Neoplasms 6

Interventions

birtamimab 1Rosiglitazone 1Melphalan 1Magnetic Resonance Imaging 1Dexamethasone 1Control Groups 1Calcium Dobesilate 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Alzheimer Disease × Dexamethasone × Clear all
NCT01083316 2020-09-25

Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis

Boston Medical Center

Phase 2 Completed
35 enrolled 9 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡